Showing results 1 to 2 of 2
Title | Author(s) | Issue Date | |
---|---|---|---|
Five-Year Outcomes with Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score ‡ 50% Journal:Journal of Clinical Oncology | 2021 | ||
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer Journal:New England Journal of Medicine | 2016 |